

Ohio Vaccines for Children (VFC) Vaccine Education

November 21, 2024

Antoinette Yuhas, Public Health Nurse Specialist

Keith Halstead, VFC Consultant Central West Region

Sarah Duade, Quality Improvement, Education and Assessment Manager

Jeremy Budd, Vaccine Preventable Disease Epidemiologist

Clay Fannin, Health Planning Administrator

Agenda

- Welcome.
- Objectives.
- Vaccine Updates.
- VFC New Storage Unit Review Form.
- Measles Surveillance and Prevention in Ohio.
- VFC Reminders and Updates.
- Pre-submitted Questions.

Objectives

At the end of the webinar, vaccine providers should:

- Be aware of VFC vaccine and program updates.
- Know the process for requesting use of a new storage unit for VFC vaccines.
- Become familiar with the effects of global health on the local level.

VFC Vaccine Updates

What's new in the world of VFC immunizations.

Immunization Update

- COVID-19 Vaccines 2024-2025.
- RSV Vaccines to Protect Infants.
- Meningococcal B Vaccine.

COVID-19 Vaccines 2024-2025

Source: <https://www.cdc.gov/vaccines/covid-19/info-by-product/index.html>

Moderna/Spikevax 2024-2025 COVID-19 Vaccine

Moderna has two presentations for their mRNA 2024-2025 COVID-19 vaccine.

Spikevax for ages 12 years and older.

Moderna for ages 6 months – 11 years.

Moderna/Spikevax 2024-2025 COVID-19 Vaccine

Moderna/Spikevax 2024-2025 COVID-19 vaccine ships **frozen**.

- Store vaccine frozen until ready to use.
- May store in a vaccine refrigerator for **up to 60 days**; be mindful of written expiry date.
- Check the expiry on carton and syringe; **do not give expired vaccine!**
- May keep at room temperature for a total of **12 hours**.
 - May return to refrigerator conditions but track how long vaccine was kept at room temperature; cumulative total at room temperature time of **12 hours**, then must discard.

Pfizer-BioNTech/Comirnaty 2024-2025 COVID-19 Vaccine

Pfizer-BioNTech has three presentations for the 2024-2025 COVID-19 vaccine.

Comirnaty for ages 12 years and older.

Pfizer-BioNTech COVID-19 vaccine for children 5 through 11 years.

Pfizer-BioNTech COVID-19 vaccine for children 6 months through 4 years.

Pfizer-BioNTech/Comirnaty 2024-2025 COVID-19 Vaccine

Pfizer-BioNTech has three presentations for their mRNA 2024-2025 COVID-19 vaccine.

Comirnaty is shipped **refrigerated**, prefilled syringes.

After removing the tip cap and attaching an appropriate needle, the glass prefilled syringe should be used immediately. If it cannot be used immediately, it must be used within 4 hours. DO NOT FREEZE.

Pfizer-BioNTech 2024-2025 COVID-19 Vaccine

Pfizer-BioNTech for young children and infants are shipped **ultra-low temperature cold frozen** single dose vials and multidose vials.

- Once moved to a refrigerator, there is a **10-week expiry date from the day it is placed in the refrigerator.** This should not exceed the expiration date printed on the vial and cartons.

May be stored at room temperature for a **total of 12 hours prior to the first puncture; multidose vials are discarded 12 hours post access.**

Novavax COVID-19 Vaccine 2024-2025

- Novavax COVID-19 protein-subunit vaccine for 2024-2025 ships **refrigerated**.
- Store Novavax in the refrigerator until expiry.
- Prefilled syringes.
- Remember, an unvaccinated person will require a series of TWO doses separated by 21 days.



[FDA package insert.](#)

[Novavax image.](#)

Respiratory Syncytial Virus (RSV) Vaccines

ABRYSVO: Infant Protection Through Maternal Vaccination



Pfizer's ABRYSVO is **the only RSV vaccine approved for maternal vaccination** to prevent RSV in infants.

- ABRYSVO for maternal vaccination is administered to pregnant women in their **gestational weeks 32 through 36 and six days**.
- Infants born to mothers who received ABRYSVO will **most likely not** require Beyfortus vaccination at birth.

ABRYSVO may be received during one pregnancy only.

- If the mother received ABRYSVO during pregnancy and gave birth, then becomes pregnant again, the **following child or children will receive Beyfortus**.

ABRYSVO Storage and Handling


Once the vaccine is reconstituted, **begin a four-hour beyond-use date clock.**

Reconstituted vaccine must be used **within four hours.**

- **DO NOT put it back in the refrigerator after reconstitution.**
- When the **four hours have passed**, the dose must be **wasted and disposed.**
- Do not administer expired vaccine.



Timing of Abrysvo and Beyfortus Administration



Monoclonal Antibody For Infants (Beyfortus)


First RSV Season - One Dose For Infants

One dose of Beyfortus is recommended for infants younger than 8 months of age who were born shortly before or are entering their first RSV season (typically fall through spring) if an infant meets any criteria below:

- **The mother did not receive an ABRYSVO vaccination during pregnancy.**
- **The mother's RSV vaccination status is unknown.**
- **The infant was born within 14 days of maternal RSV vaccination.**

Beyfortus Season One

- Beyfortus is given during the infant's **first RSV season** before they are 8 months old.
- The dose is based upon their weight.
 - If the infant is **less than 5 kilograms**, they receive a **50mg/0.5mL/IM**.
 - If they weigh **5 kilograms or more**, they will receive **100mg/1.0mL/IM**.



RSV Season Two - For Older Infants

- For **RSV season two** infants and young children 8 months through 19 months of age, who are at increased risk, will receive a total dose of **200mg**.
- That is achieved by giving **two, 100mg/1.0mL** doses (one dose in each leg).
- Regardless of body weight.
- Children ages 8 months and older **who are not at increased risk** of severe RSV disease **should not receive** Beyfortus for their second season.

Second Season








Eight
through 19
months old
who are at
increased
risk

200 mg
administered as
two IM
injections of
100mg/mL.


Beyfortus

The correct dose by weight must be used.

- You **cannot use** two 50mg doses if a 100mg dose is required.
- You **cannot use** half of a 100mg dose if 50mg dose is required.



2



Department of
Health

Meningococcal B

Meningococcal B Vaccines

**Meningococcal B vaccines
are not interchangeable!**

Meningococcal B Vaccines

On August 19, 2024, the Food and Drug Administration approved a new dosing schedule for Bexsero^(R).

- **Two-dose schedule:** Administer Bexsero (0.5 mL) at zero and six months. If the second dose is administered earlier than six months after the first dose, a third dose should be administered at least four months after the second dose.
- **Three-dose schedule:** Administer Bexsero (0.5 mL) at zero, one to two (1-2) months, and six (6) months.

Meningococcal B Vaccine: Bexsero

Bexsero			
Dose Schedule.	Spacing of intervals between doses.		
	Dose One	Dose Two	Dose Three
Two-dose	Initial	Six months	If dose two is < six months, give dose three a minimum of four months from dose two.
Three-dose	Initial	One – Two months	Six months.

VFC Vaccine Storage Review Form

Vaccine Storage Unit Review Form

VFC Program created a [Vaccine Storage Unit Review Form](#).

Sites will need to download, complete, and submit the form when purchasing new or replacement storage units that will store VFC vaccines.

Vaccine Storage Unit Review Form



Purpose:

- To ensure newly purchased or replacement unit(s) are properly vetted prior to placing VFC vaccines in storage unit(s).
- Receive ODH approval of the storage unit(s) prior to using it for vaccine storage.
- Ensure that storage unit(s) being used at VFC sites are compliant with CDC storage and handling protocols and best practices.
- **Dorm style units cannot be used to store VFC vaccines.**

VFC Vaccine Storage Unit Review Form



Provider Name:		County:	[Choose a County]
Provider Pin #:		VFC Consultant:	

Vaccine Storage Unit Description Name this unit with a description that will allow your staff to easily identify it in the event of follow-up. ODH recommends using the brand and serial number (e.g., GE - S1234567). If there are additional storage units, complete the additional unit description on page 2.	
Vaccine Storage Unit A:	
Type of unit.	[Choose Unit Type]
Indicate type of use for vaccine storage if "Stand-alone".	[Choose Stand-Alone Type]
Indicate type of use for vaccine storage if "Combination".	[Choose Combination Type]
Vaccine storage grade.	[Choose Storage Grade]
Photo of the front of the unit with door closed.	
Photo of the front view of the unit with door open.	

Note - The Centers for Disease Control and Prevention (CDC) recommends the following units, in order of preference, for the storage of VFC vaccines:

- Purpose-built or pharmaceutical/medical-grade units, including doorless and vending-style units.
- Stand-alone refrigerator and freezer units – these units can vary in size from a compact, under-the-counter style to a large, stand-alone, pharmaceutical-grade storage unit.
- Combination household refrigerator/freezer unit, using only the refrigerator compartment to store vaccines – a separate stand-alone freezer should then be used to store frozen vaccines.

The use of dormitory-style units is prohibited for VFC provider offices. These units have a single exterior door and an evaporator plate or cooling coil, that is usually located in an icemaker or freezer compartment.

[CDC Vaccine Storage and Handling Toolkit](#)

Vaccine Storage Unit Review Form



Vaccine Storage Unit Review Form

VFC Vaccine Storage Unit Review Form



Provider Name:		County:	[Choose a County]
Provider Pin #:		VFC Consultant:	

Vaccine Storage Unit Description Name this unit with a description that will allow your staff to easily identify it in the event of follow-up. ODH recommends using the brand and serial number (e.g., GE - S1234567). If there are additional storage units, complete the additional unit description on page 2.	
Vaccine Storage Unit A:	

Click on the “Choose a County” space. A dropdown menu will appear. Select your county.

Provider Name, Provider PIN #, VFC Consultant name are free form and may be entered directly into the appropriate fields.



Vaccine Storage Unit Review Form

Vaccine Storage Unit Description

Name this unit with a description that will allow your staff to easily identify it in the event of follow-up.

ODH recommends using the brand and serial number (e.g., GE - S1234567).

If there are additional storage units, complete the additional unit description on page 2.

Vaccine Storage Unit A:

Type of unit.

[Choose Unit Type]



Indicate type of use for vaccine storage if “Stand-alone”.

[Choose Stand-Alone Type]



Indicate type of use for vaccine storage if “Combination”.

[Choose Combination Type]



Vaccine storage grade.

[Choose Storage Grade]




Properly document the branding and type of the storage unit(s).

ODH recommends using the brand and serial number (e.g., ABS 12634).



Department of
Health

Vaccine Storage Unit Review Form

Vaccine Storage Unit Description	
Name this unit with a description that will allow your staff to easily identify it in the event of follow-up. ODH recommends using the brand and serial number (e.g., GE - S1234567). If there are additional storage units, complete the additional unit description on page 2.	
Vaccine Storage Unit A:	
Type of unit.	[Choose Unit Type] 
Indicate type of use for vaccine storage if "Stand-alone".	[Choose Unit Type]
Indicate type of use for vaccine storage if "Combination".	Stand-alone
Vaccine storage grade.	Combination
	Doorless/Vending Style Unit
	Ultra-cold Freezer
	Dorm-style Unit

Type of Unit may be selected from the dropdown menu.

Vaccine Storage Unit Review Form

Vaccine Storage Unit Description Name this unit with a description that will allow your staff to easily identify it in the event of follow-up. ODH recommends using the brand and serial number (e.g., GE - S1234567). If there are additional storage units, complete the additional unit description on page 2.	
Vaccine Storage Unit A:	
Type of unit.	[Choose Unit Type]
Indicate type of use for vaccine storage if "Stand-alone".	[Choose Stand-Alone Type]
Indicate type of use for vaccine storage if "Combination".	[Choose Stand-Alone Type] Refrigerator
Vaccine storage grade.	Freezer
	N/A

Depending on the type of unit, complete either "Stand-alone" or "Combination" to indicate the specific use of the unit.

Select the dropdown for "Type of Use" for vaccine storage.

Vaccine Storage Unit Review Form

Vaccine Storage Unit Description Name this unit with a description that will allow your staff to easily identify it in the event of follow-up. ODH recommends using the brand and serial number (e.g., GE - S1234567). If there are additional storage units, complete the additional unit description on page 2.	
Vaccine Storage Unit A:	
Type of unit.	[Choose Unit Type] ▼
Indicate type of use for vaccine storage if "Stand-alone".	[Choose Stand-Alone Type] ▼
Indicate type of use for vaccine storage if "Combination".	[Choose Combination Type] ▼
Vaccine storage grade.	[Choose Storage Grade] ▼
Photo of the front of the unit	<div>[Choose Storage Grade] Pharmaceutical Commercial Household (Non-Commercial) Purpose-Built (e.g. doorless/vending style unit)</div>

Select the dropdown for the grade of the storage unit.

Vaccine Storage Unit Review Form

<p>Photo of the <u>front</u> of the unit <u>with door closed.</u></p>	
---	---

Click here to browse your files and upload the photo of the **FRONT** of your storage unit with the door **CLOSED**.



Vaccine Storage Review Form

<p><u>Photo of the front view of the unit with door open.</u></p>	
---	---

Click here to upload the photo of the **FRONT** of your storage unit with the door **OPENED**.



Overview of the Process

The VFC-enrolled provider will:

- Complete the Storage Unit Review form with information about the storage unit.
- Use a back up DDL to monitor and collect temperatures in the new storage unit.
- Submit the completed form via email to vfc@odh.ohio.gov **and** include data file with at least two days of recorded temperatures from the unit.
- Wait to hear back from ODH VFC Program on unit approval before storing VFC vaccine in the unit. Approval will come via email.

ODH Administrative Review Section

This section will be completed by the ODH VFC team upon review.

Once completed, submit this form to VFC@odh.ohio.gov. The ODH VFC Team will reach out to you and request temperature data for the storage unit.

Note: The vaccine storage unit should not be used until it has been approved by the ODH VFC Program.

ODH VFC Program Administrative Review	
Select the date of storage unit review.	
Name of VFC staff reviewer.	
Is the unit approved for vaccine storage?	[Is Unit Approved]
Select the date ODH requested temperature data from VFC provider.	
Select the date temperature data was received by ODH.	
Are temperatures stable for vaccine storage?	[Are Temperatures Stable?]
Notes:	

HEA 3526 – (Revised 9/2024)

Vaccine Storage Review Form

Note: Storing VFC vaccines in an unapproved CDC storage unit may affect vaccines efficacy.

- After the unit is approved, Wi-Fi Data logger(s) will need to be installed and/or moved to the new unit(s).
- New unit temperatures will be requested by ODH prior to use.
- Unit calibration dates must be current and available.

Global Vaccine Preventable Diseases: Measles Surveillance and Prevention in Ohio

Objectives

- Vaccine Preventable Program Overview.
- Effects of Global Health on the Local Level.
- Global Measles Activity and Risk in the United States.

Who We Are

How Our Programs Work Together to Prevent or Control the Spread of Vaccine Preventable Diseases (VPDs)

VPD Program

- Reviews and classify VPDs in the Ohio Disease Reporting System.
- Provides guidance to local health departments and providers.
- Provides data to stakeholders and the public on VPD disease trends in Ohio (e.g., online Summary of Infectious Diseases in Ohio dashboard).
- Works with the Ohio Department of Health Laboratory for VPD specimen testing.

Immunization Program

- Administers the VFC Program.
- Develops and maintains the statewide immunization registry.
- Provides vaccine to birthing hospitals to promote hepatitis B prevention.
- Works with healthcare providers to improve immunization rates.

Effects of Global Health on the Local Level: Measles

Measles Overview

- Symptoms appear seven to 14 days after exposure.
 - High fever.
 - Cough.
 - Runny nose (coryza).
 - Red, watery eyes (conjunctivitis).
 - Rash.
- Healthcare providers are required to report suspected measles cases to their local health department.
- Laboratory results are crucial for identifying cases. Testing can be coordinated by public health.

Measles Overview

- Approximately three out of 10 people who are infected with measles will have a complication.
- Complications include:
 - Ear infections.
 - Pneumonia.
 - Encephalitis (swelling of the brain).
 - Hemorrhagic measles.
 - Clotting disorders.
 - Death.

How Measles Spreads

- Measles spreads through the air when an infected person coughs or sneezes.
- Measles is very contagious.
 - You can get measles just by being in a room where a person with measles has been. This can happen even up to two hours after that person has left.
 - You can spread measles to others from four days before through four days after the rash appears.

One person with measles can spread it to nine out of 10 unprotected people around them.



Treatment

- There is no specific antiviral therapy for measles.
- Medical care is supportive and helps to relieve symptoms or complications, such as bacterial infections.

Measles Prevention

Measles, Mumps, Rubella (MMR) Vaccine


- Recommended two-dose series in the United States.
 - First dose at 12 to 15 months.
 - Second dose at 4 to 6 years.
- Two doses of MMR vaccine are about **97%** effective at preventing measles; one dose is about **93%** effective.
- Possible side effects of the vaccine:
 - Some may develop soreness in local area of the shot, occasional low-grade fever.
 - Rare high-grade fever.

Herd Immunity

- **Herd immunity:** the level of protection from either previous infections or vaccination needed in a population to prevent the spread of a disease.
- Because measles has such a high infectivity rate, the threshold for community protection (herd immunity) is also very high, requiring **at least 95%** to prevent epidemics.

MMR Vaccine is Highly Effective

Reported Measles Cases in the United States from 1962 – 2023*



*2023 data are preliminary and subject to change. †Elimination is defined as the absence of endemic measles transmission in a region for at least 12 months in the presence of a well-performing surveillance system.

Source: https://www.cdc.gov/measles/data-research/?CDC_Aaref_Val=https://www.cdc.gov/measles/cases-outbreaks.html

Global Measles Activity and Risk in the United States

Global Measles Cases and Outbreaks Are On the Rise


- At local levels in the U.S., pockets of unvaccinated people can exist even in states with high vaccination coverage.
- Measles cases are increasing globally.
- A global society results in the increased chance of importation of cases to the U.S.
- Outbreaks can occur in communities with low MMR vaccination coverage and pockets of unvaccinated people.

Global Vaccination Rates - Post Pandemic

- Vaccination coverage plateaued in the decade prior to the COVID-19 pandemic.
- COVID-19 caused additional disruptions in routinely recommended vaccinations efforts and strained healthcare systems.
- Although there have been some minor increases since 2021, vaccination levels have not returned to pre-pandemic coverage rates.
- By the end of 2023, 83% of children (globally) had received one dose of measles-containing vaccine by their second birthday, and 74% of children (globally) received two doses of measles vaccine.

U.S. Measles Outbreak Risks Depend on Two Factors

1. Global measles activity.
2. U.S. MMR vaccine coverage.




Top 10 Countries With Measles Outbreaks


Country	Number of Cases
Iraq	16,560
Pakistan	16,522
Ethiopia	14,977
Yemen	11,986
India	11,360
Kazakhstan	11,242
Russian Federation	10,359
Romania	7,906
Kyrgyzstan	7,499
Afghanistan	5,488

Source: World Health Organization. The data reflected covers March 2024 - August 2024.

Close-Knit and Under-Vaccinated Communities




Confirmed Measles Cases, by Month of Rash Onset (N=338), U.S., January 1, 2020-March 28, 2024



Source: https://www.cdc.gov/mmwr/volumes/73/wr/mm7314a1.htm#F1_up

Confirmed Measles Cases by Year, Ohio, 2014-2024 YTD*




Source of disease data: Ohio Disease Reporting System (ODRS).

Measles Surveillance in Ohio


- VPD Epidemiology provides guidance to local health departments and healthcare providers.
- VPD Epidemiology reports case data to the Centers for Disease Control and Prevention (CDC).
- VPD Epidemiology reports case recent travel (when applicable) to the Division of Global Migration Health (DGMH).
- VPD Epidemiology works with the ODH Immunization Program to provide MMR vaccine for vaccination clinics.
- VPD Epidemiology coordinates specimen submission for measles testing at the Ohio Department of Health Laboratory (ODHL).

Coverage for 24-Month-Olds with at least one dose of MMR vaccine



Source: [National Immunization Survey](#)

Coverage for Ohio Kindergartners with at least two doses of MMR vaccine



Source: [Ohio Department of Health](#)

Strategies to Increase MMR Vaccine Coverage in Your Practice

- Assess MMR vaccine history at every appointment.
- Recommend the MMR vaccine at every visit.
- Identify patients who are coming due or overdue for an MMR vaccine dose.

Strategies to Increase MMR Vaccine Coverage in Your Practice


- Send reminders to those coming due. Recall those who are overdue.
- Did you know Impact SIIS has a reminder/ recall tool that your office can use?
- To learn more contact Impact SIIS at 1-844-963-4829 or visit the Impact SIIS Document Center for user guidance.

Strategies to Increase MMR Vaccine Coverage in Your Practice

- Want to know about your own clinic's MMR coverage rates?
- Interested in learning additional strategies to increase your coverage rates?
- Consider participating in the no-cost Immunization Quality Improvement for Providers (IQIP) program.
- For more information, please contact the ODH Immunization Program at 1-800-282-0546 or immunize@odh.ohio.gov.

Resources

- CDC Measles, Mumps, and Rubella (MMR) Vaccination - Information for Healthcare Providers:
<https://www.cdc.gov/vaccines/vpd/mmr/hcp/index.html>.
- MMR Vaccine Information Statements - English and Translations:
<https://www.immunize.org/vaccines/vi/s/mmr/>.



Take-aways

- Measles is extremely contagious and can be life-threatening.
- Measles cases are increasing world-wide.
- Although the risk is low for a large outbreak in the general, vaccinated population in the U.S, close-knit and under-vaccinated communities are at risk for large outbreaks.
- The MMR vaccine is extremely effective and safe.
- Vaccination coverage has dropped since the COVID-19 pandemic both globally and in the U.S.
- If coverage rates remain below 95%, the risks of potential outbreaks will continue.

VFC Reminders and Updates

What's new in the world of VFC Program.

VFC Reminders and Updates

- Report temperature excursions to the Immunization Program Main Line (1-800-282-0546).
- Notify ODH VFC Program of VFC Coordinator staff turnover or address changes.
- Submit a vaccine transfer form to return any spoiled or wasted VFC vaccines.

VFC Ordering Reminders

- Note office hour updates in VOMS when placing a vaccine order.
- Include min/max temperatures **SINCE LAST ORDER DATE** in the comments section of VOMS.
- Providers can order RSV and COVID vaccine off-cycle, as needed.
 - Ohio is receiving weekly/biweekly allocations of RSV products. These are available to order until the supply is exhausted or until the next allocation is received.
 - As we continue through the RSV season Ohio's allocation will shift to a larger amount of 50mg presentation and fewer 100mg presentation. Please assure your location is ordering 100mg product.

December Vaccine Ordering Reminders:

- VFC and 317 vaccine ordering will be limited during the upcoming holidays. In anticipation of the holiday shipping/delivery schedule, providers should plan accordingly to ensure appropriate vaccine inventory
- It is recommended that providers maintain a minimum of four weeks of inventory to prevent vaccine outages if orders are delayed due to weather and/or carrier interruptions.

December Vaccine Ordering Information:

Monday	Tuesday	Wednesday	Thursday	Friday
December 23 Limited	December 24 Limited	December 25 NO Deliveries	December 26 NO Deliveries	December 27 Limited
December 30 Limited	December 31 Limited	January 1 NO Deliveries	January 2 NO Deliveries	January 3 Routine Deliveries Resume

Vaccine orders must be submitted in VOMS by noon Thursday, December 12, 2024. Orders placed after this date may not ship prior to January 2025.

There will be no orders delivered from McKesson between December 23, 2024, and January 2, 2025. Limited direct shipment deliveries from Merck (frozen - Varivax or ProQuad) and Pfizer (COVID-19 vaccine) may occur during this time.

ODH VFC Website: VFC Email Communications

- ODH VFC Program has shifted to email communications with our enrolled providers. The emails are sent from vfc@odh.ohio.gov
- Most communications will be available on our ODH VFC website for providers to view.
- Please assure that your site is able to receive emails from this address.

Resources

- **ABRYSVO.**

- [Pfizer's ABRYSVO for Professionals.](#)
- [ABRYSVO package insert.](#)
- [Healthcare Providers: RSV Vaccination for Pregnant People | CDC.](#)
- New RSV VIS 10/17/2024: [RSV Vaccine VIS | Vaccines & Immunizations | CDC.](#)

- **Beyfortus.**

- [Nirsevimab Immunization Information Statement \(CDC\).](#)

- **Meningococcal B.**

- [CDC Meningococcal Vaccine Recommendations.](#)
- [FDA Approval for Bexsero second dose interval.](#)
- [Bexsero package insert.](#)

Resources

- **CDC/Health and Human Services (HHS) Resources.**
 - [CDC MMWR Report on RSV Vaccines.](#)
 - [CDC RSV Recommendations.](#)
 - [Immunize.org Storage and Handling.](#)
 - [VAERS Reporting for Professionals.](#)
 - COVID-19 VIS: [Vaccine Information Statement: COVID-19.](#)
 - COVID-19 Interim Clinical Considerations: [Clinical Guidance for COVID-19 Vaccination | CDC.](#)
- **Ohio Department of Health.**
 - Telephone: (614)466-4643.
 - (Ohio only): 1-800-282-0546.
 - VFC Email: vfc@odh.ohio.gov.
 - [Vaccines for Children \(VFC\) | Ohio Department of Health.](#)
 - [VFC Consultant Map.](#)

QUESTIONS?

[ODH.OHIO.GOV](https://odh.ohio.gov)



**Department of
Health**



**Department of
Health**